title: PML nuclear bodies: regulation, function and therapeutic perspectives.
abstract: PML nuclear bodies (NBs) were first described by electron microscopy and rediscovered through their treatment-reversible disruption in a rare leukaemia. They recruit multiple partner proteins and now emerge as interferon- and oxidative stress-responsive sumoylation factories. NBs mediate interferon-induced viral restriction, enhance proteolysis, finely tune metabolism and enforce stress-induced senescence. Apart from being markers of cellular stress, PML NBs could be harnessed pharmacologically in a number of conditions, including cancer, viral infection or neurodegenerative diseases.
authors.affiliation: Université Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, Paris, France; INSERM UMR 944, Equipe Labellisée par la Ligue Nationale Contre le Cancer, Institut Universitaire d'Hématologie, Hôpital St. Louis, Paris, France; CNRS UMR 7212, Hôpital St. Louis, Paris, France.
authors.forename: Umut
authors.initials: U
authors.lastname: Sahin
authors.forename: Valérie
authors.initials: V
authors.lastname: Lallemand-Breitenbach
authors.forename: Hugues
authors.initials: H
authors.lastname: de Thé
mesh_terms: D000818:Animals; D006801:Humans; D045586:Intranuclear Inclusion Bodies; D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins
chemical_list: D009687:Nuclear Proteins; D000071156:Promyelocytic Leukemia Protein; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins; C070576:PML protein, human
keywords: PML; RNF4; arsenic; interferon; oxidative stress; p53; senescence